

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions of claims in the application.

Listing of Claims

1. (Currently Amended) A method for treating deafness in a subject, comprising administering to said subject a pharmaceutical composition that comprises (a) at least one CDK/cyclin kinase inhibitor that is a purine derivative or a pharmaceutically acceptable salt thereof and (b) a pharmaceutically acceptable carrier, wherein (i) said subject suffers deafness due to death of sensory hair cells and (ii) said composition is administered in an amount effective for inducing differentiation of supernumerary hair cells and Deiters' cells in an organ of Corti of said subject.
2. (Cancelled)
3. (Previously Presented) The method of claim 1, wherein said purine derivative is selected from the group consisting of roscovitine, indirubin and purvalanol.
4. (Previously Presented) The method of claim 1, wherein said kinase inhibitor is administered parenterally, rectally, topically, transdermally or orally.
5. (Previously Presented) The method of claim 4, wherein said kinase inhibitor is administered by oral or by injectable route.
6. (Previously Presented) The method of claim 5, wherein said kinase inhibitor is in the form of a lozenge, a compressed tablet, a pill, a tablet, a capsule, drops, a syrup, a suspension or an emulsion.
7. (Previously Presented) The method of claim 1, wherein said pharmaceutical composition comprises 100 to 1000 mg of said kinase inhibitor or said salt per dose unit.
8. (Previously Presented) The method of claim 5, wherein said kinase inhibitor is administered in the form of an injectable solution for an intravenous, a subcutaneous or an intramuscular

route, formulated from a sterile or a sterilizable solution, or in the form of a suspension or an emulsion.

9. (Previously Presented) The method of claim 8, wherein said injectable solution comprises 100-1000 mg of said kinase inhibitor or said salt.
10. (Canceled)
11. (Previously Presented) The method of claim 7, wherein said pharmaceutical composition comprises 300-600 mg of said kinase inhibitor or said salt per dose unit.
12. (Previously Presented) The method of claim 9, wherein said injectable solution comprises 300-600 mg of said kinase inhibitor or said salt.
13. (Previously Presented) The method of claim 1, wherein said salt is an acid addition salt.
14. (Previously Presented) The method of claim 13, wherein said acid is selected from the group consisting of acetic acid, ascorbic acid, maleic acid, phosphoric acid, salicylic acid and tartaric acid.